GSK

GSK
D

GSK

Arincen73/100B

GSK operating income 1985–2026

GSK's operating income in Q3 FY2026, the three months to 30 September 2026, was 2.55B GBP, down 1.7% on the same quarter a year before. GSK's operating income over the last twelve months was 6.83B GBP, down 9.3% on the twelve months before. In fiscal year 2025 it was 8.34B GBP, up 107.4% on the year before.

Last updated 7 Nov 2026 · Next report 3 Feb 2027

Operating income

Operating income · -2.1% a year over 10 yearsOperating margin

Growth

Fiscal yearPeriod endingOperating incomeGrowthOperating marginGross profitGross marginEBITDA
TTM30 Sept 20266.83B-9.29%20.40%24.42B72.96%8.73B
FY202531 Dec 20258.34B+107.36%25.52%23.65B72.40%10.40B
FY202431 Dec 20244.02B-40.39%12.82%22.33B71.16%6.67B
FY202331 Dec 20236.75B+4.85%22.24%21.76B71.76%9.08B
FY202231 Dec 20226.43B+47.65%21.94%19.77B67.42%8.60B
FY202131 Dec 20214.36B-27.13%17.64%16.53B66.95%6.49B
FY202031 Dec 20205.98B-14.11%24.55%16.43B67.44%8.07B
FY201931 Dec 20196.96B+26.96%20.62%21.89B64.85%9.43B
FY201831 Dec 20185.48B+34.16%17.79%20.58B66.77%7.35B
FY201731 Dec 20174.09B+57.31%13.54%19.84B65.74%6.18B
FY201631 Dec 20162.60B-74.83%9.32%18.60B66.69%4.43B
FY201531 Dec 201510.32B+186.96%43.15%15.07B62.99%12.89B
FY201431 Dec 20143.60B-48.82%15.64%15.68B68.17%5.16B
FY201331 Dec 20137.03B-3.73%26.52%17.92B67.61%8.80B
FY201231 Dec 20127.30B-6.49%27.62%18.51B70.02%8.81B
FY201131 Dec 20117.81B+106.37%28.51%19.74B72.07%9.88B
FY201031 Dec 20103.78B-55.10%13.32%20.49B72.18%5.62B
FY200931 Dec 20098.43B+17.98%29.70%20.99B73.98%10.24B
FY200831 Dec 20087.14B-10.05%29.32%17.94B73.66%8.73B
FY200731 Dec 20077.94B+10.48%34.91%17.53B77.08%9.22B
FY200631 Dec 20067.19B+4.68%30.95%18.21B78.43%8.76B
FY200531 Dec 20056.86B+30.52%31.70%16.89B78.00%1.27B
FY200431 Dec 20045.26B-17.61%26.33%15.62B78.18%6.61B
FY200331 Dec 20036.38B+15.00%29.81%16.88B78.81%7.24B
FY200231 Dec 20025.55B-9.05%26.17%16.60B78.27%6.54B
FY200131 Dec 20016.10B+29.06%29.72%16.09B78.38%6.92B
FY200031 Dec 20004.73B+80.15%26.16%14.12B78.09%7.11B
FY199931 Dec 19992.63B-2.16%30.92%4.16B48.95%3.21B
FY199831 Dec 19982.68B-4.93%33.61%6.44B80.65%3.23B
FY199731 Dec 19972.82B-9.90%35.36%7.98B100.00%3.29B
FY199631 Dec 19963.13B+31.49%37.55%8.34B100.00%3.65B
FY199531 Dec 19952.38B+63.85%22.71%10.49B100.00%3.26B
FY199430 Jun 19951.45B-19.99%22.43%5.58B86.05%1.78B
FY199330 Jun 19941.82B+19.15%32.13%5.66B100.00%2.16B
FY199230 Jun 19931.53B+18.49%30.93%4.93B100.00%1.96B
FY199130 Jun 19921.29B—31.42%4.10B100.00%1.68B
FY199030 Jun 19910.00—0.00%3.40B100.00%1.51B
FY198930 Jun 19900.00—0.00%3.18B100.00%1.35B
FY198830 Jun 19890.00—0.00%2.57B100.00%1.13B
FY198730 Jun 19880.00—0.00%2.06B100.00%926.00M
FY198630 Jun 19870.00—0.00%1.74B100.00%812.00M
FY198530 Jun 19860.00—0.00%1.43B100.00%661.00M

Figures in GBP. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,Net income,EPS,Shares outstanding,Cash on hand,Total debt,Free cash flow,Income statement

Common questions about GSK's operating income

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.